Search
Search Results
-
NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis
Programmed cell death-ligand 1 (PD-L1) has a significant role in tumor progression and metastasis, facilitating tumor cell evasion from immune...
-
KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
Immunotherapy has become a prominent first-line cancer treatment strategy. In non-small cell lung cancer (NSCLC), the expression of PD-L1 induces an...
-
PD-L1 expression levels in mesenchymal stromal cells predict their therapeutic values for autoimmune hepatitis
BackgroundAutoimmune hepatitis is a chronic inflammatory hepatic disorder with no effective treatment. Mesenchymal stromal cells (MSCs) have emerged...
-
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
More than half of tumor patients with high PD-L1 expression do not respond to anti-PD-1/PD-L1 therapy, and the underlying mechanisms are yet to be...
-
Expression and in vitro function of anti-PD-L1 human antibody expressed in plant
Plants can be used to produce recombinant functional proteins such as antibodies and vaccines. In this study, transgenic plants were utilized to...
-
Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity
Immunotherapies targeting the PD-1/PD-L1 axis have become first-line treatments in multiple cancers. However, only a limited subset of individuals...
-
Shedding Light on the Role of Exosomal PD-L1 (ExoPD-L1) in Cancer Progression: an Update
Exosomes are the primary category of extracellular vesicles (EVs), which are lipid-bilayer vesicles with biological activity spontaneously secreted...
-
PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief
Pain is a common symptom of many diseases with a high incidence rate. Clinically, drug treatment, as the main method to relieve pain at present, is...
-
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
The programmed cell death 1 (PD-1) signaling pathway, a key player in immune checkpoint regulation, has become a focal point in cancer immunotherapy....
-
Epigenetically modified AP-2α by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression
Programmed death-ligand 1 (PD-L1) ensures that tumor cells escape T-cell-mediated tumor immune surveillance. However, gliomas are characteristic of...
-
PRRX1 upregulates PD-L1 in human mesenchymal stem cells
Mesenchymal stem cells (MSCs) have been demonstrated to be efficacious in clinical applications for the amelioration of immune disorders, including...
-
TERC suppresses PD-L1 expression by downregulating RNA binding protein HuR
TERC is the RNA component of telomerase, and provides a template for TERT to synthesize telomere repeats at chromosome ends. Increasing evidence has...
-
The PD-1–PD-L1 pathway maintains an immunosuppressive environment essential for neonatal heart regeneration
The adult mouse heart responds to injury by scarring with consequent loss of contractile function, whereas the neonatal heart possesses the ability...
-
Proximity proteome map** reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells
BackgroundPD-L1, a transmembrane ligand for immune checkpoint receptor PD1, has been successfully targeted to activate an anti-tumor immune response...
-
EFEMP2 upregulates PD-L1 expression via EGFR/ERK1/2/c-Jun signaling to promote the invasion of ovarian cancer cells
BackgroundFibulin-like extracellular matrix protein 2 (EFEMP2) has been reported to be related to the progression of various cancers. We have...
-
USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1
The abnormal upregulation of programmed death ligand-1 (PD-L1) on tumor cells impedes T-cell mediated cytotoxicity through PD-1 engagement, and...
-
The tumor promoter cysteinyl leukotriene receptor 1 regulates PD-L1 expression in colon cancer cells via the Wnt/β-catenin signaling axis
Immunotherapy targeting programmed death-ligand 1 (PD-L1) or PD-1 in solid tumors has been shown to be clinically beneficial. However, in colorectal...
-
Phosphofructokinase 1 platelet isoform induces PD-L1 expression to promote glioblastoma immune evasion
BackgroundOverexpression of PD-L1 is observed in many types of human cancer, including glioblastoma (GBM) and contributes to tumor immune evasion. In...
-
Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy
Dual blockade of HER2 and PD-1/PD-L1 is the most promising regimen for HER2-positive patients with gastric cancer (GC); PD-L1 combined positive...
-
CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity
The interaction between glioblastoma cells and glioblastoma-associated macrophages (GAMs) influences the immunosuppressive tumor microenvironment,...
